Kringle Pharma (4884) Stock Overview
Engages in research and develops therapeutic agents for the treatment of intractable diseases in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
4884 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Kringle Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥414.00 |
| 52 Week High | JP¥1,125.00 |
| 52 Week Low | JP¥368.00 |
| Beta | 0.35 |
| 1 Month Change | 8.95% |
| 3 Month Change | 5.61% |
| 1 Year Change | -46.72% |
| 3 Year Change | -63.40% |
| 5 Year Change | -56.79% |
| Change since IPO | -65.59% |
Recent News & Updates
Shareholder Returns
| 4884 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 4.8% | 1.6% | -4.4% |
| 1Y | -46.7% | 17.0% | 33.9% |
Return vs Industry: 4884 underperformed the JP Biotechs industry which returned 17% over the past year.
Return vs Market: 4884 underperformed the JP Market which returned 33.9% over the past year.
Price Volatility
| 4884 volatility | |
|---|---|
| 4884 Average Weekly Movement | 4.8% |
| Biotechs Industry Average Movement | 8.5% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in JP Market | 8.7% |
| 10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4884 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4884's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 17 | Kiichi Adachi | www.kringle-pharma.com |
Kringle Pharma, Inc. engages in research and develops therapeutic agents for the treatment of intractable diseases in Japan. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Kita, Japan.
Kringle Pharma, Inc. Fundamentals Summary
| 4884 fundamental statistics | |
|---|---|
| Market cap | JP¥2.93b |
| Earnings (TTM) | -JP¥905.42m |
| Revenue (TTM) | JP¥72.62m |
Is 4884 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4884 income statement (TTM) | |
|---|---|
| Revenue | JP¥72.62m |
| Cost of Revenue | JP¥0 |
| Gross Profit | JP¥72.62m |
| Other Expenses | JP¥978.05m |
| Earnings | -JP¥905.42m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 11, 2026
| Earnings per share (EPS) | -123.20 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,246.73% |
| Debt/Equity Ratio | 0% |
How did 4884 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/06 11:10 |
| End of Day Share Price | 2026/03/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kringle Pharma, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyoichiro Shigemura | Nomura Securities Co. Ltd. |